Masimo - MASI Stock Forecast, Price & News

Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MASI. Needham & Company LLC lifted their price objective on Masimo from $163.00 to $179.00 and gave the stock a "buy" rating in a report on Wednesday. Piper Sandler increased their price objective on shares of Masimo from $130.00 to $135.00 and gave the company a "neutral" rating in a research note on Wednesday. Stifel Nicolaus lowered their target price on shares of Masimo from $175.00 to $150.00 in a research note on Wednesday, May 4th. Finally, StockNews.com cut shares of Masimo from a "buy" rating to a "hold" rating in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $183.80.

Masimo Price Performance

MASI Stock opened at $154.37 on Friday. The stock has a 50-day moving average price of $137.78 and a two-hundred day moving average price of $148.07. Masimo has a 1 year low of $112.07 and a 1 year high of $305.21. The stock has a market cap of $8.11 billion, a PE ratio of 46.50 and a beta of 0.98. The company has a current ratio of 2.10, a quick ratio of 3.98 and a debt-to-equity ratio of 0.77.

Masimo (NASDAQ:MASI - Get Rating) last announced its earnings results on Tuesday, August 9th. The medical equipment provider reported $1.35 EPS for the quarter, topping the consensus estimate of $1.19 by $0.16. The business had revenue of $565.30 million during the quarter, compared to analysts' expectations of $540.56 million. Masimo had a net margin of 12.68% and a return on equity of 17.39%. The firm's revenue was up 87.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.94 earnings per share. Equities analysts forecast that Masimo will post 4.47 EPS for the current fiscal year.